Drug intelligence / Profile preview

Acoin

Development stage: Unknown
Lead developer: Combustin Pharmazeutische Präparate
Modality: Small Molecules
Administration: Topical

Overview

**Acoin** is a historical fixed-dose topical local-anaesthetic formulation developed by Combustin for surface anaesthesia of mucous membranes, including use before diagnostic bronchoscopy. The formulation contains tetracaine and polidocanol. Tetracaine is an ester local anaesthetic that reversibly blocks voltage-gated sodium channels, preventing action-potential propagation in sensory nerves; polidocanol contributes local anaesthetic and mucosal-soothing effects. A Phase 3 German study compared Acoin with tetracaine alone in adults undergoing bronchoscopy. ([clinicaltrialsregister.eu](https://www.clinicaltrialsregister.eu/ctr-search/rest/download/trial/2005-001491-13/DE))

Brand names: Acoin
Other names: tetracaine + polidocanol

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on Acoin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acoin.

Explore the full profile